Form 13-F position report

INNOVATE BIOPHARMACEUTICLS

Reported by MILLENNIUM MANAGEMENT LLC

NMTRQ CUSIP 45782F105 Manager CIK 0001273087

Reported 0 shares, down 95,262 (100.0%) from the prior quarter.

Reported value -100.0%; share count -100.0% vs. the prior quarter.

Reduced
% of reported 13F value 0 This manager · Q3 2019
Shares 0 Quarter-end amount reported
Reported value $0 Fair value at quarter end
Consecutive quarters held 2 Through Q3 2019

Reported position value by quarter

Reported position value by quarter

Each bar is a Form 13-F quarter-end snapshot. It does not show trades made within the quarter.

Reported position value by quarter
Date Holding Value

Quarterly position history

How this manager's reported quarter-end position changed over time.

0 quarters
Quarterly reported position history for INNOVATE BIOPHARMACEUTICLS held by MILLENNIUM MANAGEMENT LLC.
Quarter Activity Shares Change % of reported 13F Reported value Filed Source filing
This position's reported history falls outside the five-year preview window. A free account unlocks it. Unlock full history

Who else reported the position

32 managers reported INNOVATE BIOPHARMACEUTICLS for Q3 2019.

Managers reporting INNOVATE BIOPHARMACEUTICLS in Q3 2019.
Manager Activity Shares Change % of reported 13F Reported value Tenure
SABBY MANAGEMENT LLC Reduced 1,248,814 -87,434 0.72% $1,336,000 2 qtrs
VANGUARD GROUP INC Reduced 730,130 -225,014 < 0.01% $781,000 6 qtrs
BlackRock Inc Reduced 341,807 -4,983 < 0.01% $365,000 7 qtrs
GEODE CAPITAL MANAGEMENT LLC Reduced 113,968 -2,662 < 0.01% $121,000 6 qtrs
MORGAN STANLEY Reduced 63,807 -8,755 < 0.01% $68,000 7 qtrs
NORTHERN TRUST CORPORATION Reduced 27,519 -165,945 < 0.01% $29,000 6 qtrs
BREWIN DOLPHIN Ltd Unchanged 25,000 0 < 0.01% $26,750 2 qtrs
Summit X LLC New 19,000 +19,000 < 0.01% $19,000 1 qtr
Virtu Financial LLC Reduced 17,075 -45,747 < 0.01% $18,000 2 qtrs
THE BANK OF NEW YORK MELLON CORPORATION Unchanged 14,692 0 < 0.01% $16,000 6 qtrs
Premium adds each manager's conviction percentile across reporting peers.
Filing details and methodology As reported
Report period
September 30, 2019
Filed
November 14, 2019
Filing type
13F-HR
Position type
COM PAR

Voting authority reported

No voting-authority amounts were reported for this position. Voting authority is not required for reported call options.

Form 13-F is a delayed quarter-end snapshot of disclosed long Section 13(f) securities. It can be filed up to 45 days after quarter end, excludes short positions and most non-U.S. securities, and does not reveal intra-quarter trading. For options, reported shares and value describe the underlying-share exposure; strike, expiry, premium, and written positions are not disclosed.